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Current cell therapy product limitations include the need for in-depth product understanding to ensure
product potency, safety and purity. New technologies require development and validation to address is-
sues of production scale-up to meet clinical need; assays are required for process control, validation and
release. Prior to clinical realization, an understanding of production processes is required to implement
process changes that are essential for process control. Identification of key parameters forms the ba-
sis of process tolerances, allowing for validated, adaptive manufacturing processes. This enables greater
process control and yield while withstanding regulatory scrutiny. This report summaries key milestones
in specifically for ventral midbrain dopaminergic neuroprogenitor differentiation and key translational
considerations and recommendations to enable successful, robust and reproducible current cell therapy
product-manufacturing.
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The regenerative medicine and cell therapy industries are growing exponentially; both in terms of research and
economic investment [1,2]. Their potential is not yet realized, partly due to the many process challenges developers
encounter. Cell therapy products (CTPs) and regenerative medicine are inherently multidisciplinary and thus many
aspects retard progress, from both process and manufacturing development standpoints. For the purpose of this
review, the development of a CTP for the treatment of Parkinson’s disease (PD) will be used as an exemplar study.
PD is hallmarked by the depletion of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc)
of the midbrain, which produces the catecholamine neurotransmitter dopamine [3,4]. Dopamine is involved in
neuromodulation, reward behaviors and motor utility of direct and indirect movement pathways [5]. Decreased
DA density (specifically A8, A9 and A10 cells groups) and reduced dopamine results in diminished function of the
nigrostriatal pathway and concomitant motor problems including hypokinesia, rigidity and tremors [4–9]. Additional
motor-related symptoms experienced by PD patients include stooped posture, lack of facial expression, gait changes
and dysphagia, while depression, dementia and sleep disturbances are typical nonmotor PD symptoms [4,10].
Therapies for the treatment of PD
Current treatments for PD primarily concern dopamine, predominantly by introducing exogenous dopamine to
increase levels within the brain, or preventing its degradation thus increasing bioavailability; or stimulating dopamine
receptors via an agonistic effect. Akin to all drugs, PD drugs have several potential side effects, including: liver
toxicity, sleep disturbances, hallucinations, delusions, dyskinesia and sometimes impulsive/compulsive behaviors [4].
In addition, prolonged use of medication therapy generally results in polypharmacy in order to ease the side effects of
PD drugs such as anxiety and constipation [11]. As PD is progressive, pharmaceutical efficacy diminishes over time;
resulting in increased dose strength and dosing frequency, which ultimately becomes inadequate as the symptoms
become more pronounced. Furthermore, the therapeutic window in which patients are ‘on’ decreases, resulting in
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an increase of patient ‘off ’ periods (a period in which the effect of the drug ceases prior to the next dose) and
occurrences of dyskinesia caused by dosage increases [12].
Current trials have demonstrated that DA cell replacement can result in long-term survival (≥24 years) of
engrafted cells, which efficiently re-innervate the ventral mesencephalon into the dorsal striatum. This DA trans-
plantation, engraftment and reinnervation mechanism of action (MOA) culminates in restored DA synthesis and
release, providing long-term clinical improvement ≥14 years, demonstrating proof-of-concept [13,14]. However, re-
sults are variable, despite many successes afforded for some of the patients that have undergone the transplantation
procedures [15]. One major variant is the fetal material sourcing; highlighting requirements for optimized, stan-
dardized cell preparations. Fetal tissue-based therapies pose regulatory, reproducibility and ethical challenges [15–17].
Therefore, efforts are underway to produce ventral midbrain dopaminergic (vmDA) progenitors from sustainable
and less ethically constrictive sources. This has resulted in protocol generation for human embryonic stem cells
(hESC)-derived vmDA neuroprogenitors, with comparative efficacy and potency to fetal-derived equivalents [18].
It is important to note that transplantation trials have also been carried out using alternative cell sources, including
induced pluripotent stem cells (iPSCs), parthenogenetic-derived DA neurons and neural stem cells [15,19,20].
However, the focus of this review will be hESC-derived cells due to their close relationship with current on-going
research being carried out by the authors. Furthermore, the use of hESCs is pertinent since hESC-derived DA
products are being developed commercially by companies, such as BlueRock Therapeutics, which was funded with
vast amounts of money (US$225 million) to progress CTP treatments [21]. BlueRock’s pipeline includes a H9
hESC-derived DA progenitor product, which will be commencing first-in-human clinical trials this year [19,22].
In comparison with iPSCs, hESCs face hurdles such as ethical and legal barriers restricting their use in some
countries, for example France, Germany and the USA [23–25]. Furthermore, hESCs require human leukocyte
antigen compatibility assessment, which is not necessary for patient derived iPSCs [26]. Nonetheless, hESCs are
a cell type that have been studied for decades, unlike iPSCs which were introduced in 2006 [27]. There are still
issues such as epigenetic and genetic aberrations, concomitant with the reprogramming process of iPSCs that needs
to be addressed [26,28]. In addition, the DNA integrity of iPSCs and premature senescence of some iPSC-derived
cells types has highlighted concerns regarding use of iPSC-derived products, in terms of their therapeutic safety
and stability [29]. Moreover, in comparison with hESCs, iPSCs have been shown to produce reduced cell yields
and increased variation in neuronal lineage differentiation processes [28,30], resulting in less consistency in the cell
cultures. Thus, it is in the opinion of the authors that presently hESCs are a preferable cell source for vmDA
transplantation, until iPSCs have been further studied in order to better demonstrate their genetic stability and
safety. Further details regarding the comparisons of hESCs and iPSCs and their suitability as CTP cell sources can
be found in reviews by Narsinh et al., Bilic and Belmonte and Bai et al.
An understanding of the developmental cues of the ventral mesencephalon, in particular, the cues that guide
neurulation and mesencephalic development, has enabled the establishment of in vitro protocols that reliably
produce transplantable vmDA neuroprogenitors cells. Refinement of these differentiation protocols has resulted in
transplantable vmDA neuroprogenitors, derived from hESCs [16,31]. Hegarty et al. and Arenas et al. provides an in-
depth review and primer, respectively, offering comprehensive vmDA generation and development knowledge [32,33].
However, work is still required regarding product quality optimization and reproducible manufacturing processes.
Therefore, rigorous characterization studies are required to ensure high safety and efficacy standards of the final
product.
In vitro differentiation of human embryonic stem cells into ventral midbrain dopaminaergic
neurons
Current cell replacement strategies are often hindered by ethical issues, reproducibility and cell source sustainability,
availability and quality [15,34,35]. This has led to a plethora of work providing protocols to produce neural cell
lineages, from embryonic and other pluripotent cell lines, for use in disease modeling and/or transplantation
(Figure 1A) [36–38]. The resulting cells are similar to fetal cells, concerning morphology, surface antigen, protein
expression, functionality, potency, growth and reinnervation [18,39,40].
The protocols examined in this review utilize hESCs. Other sources have been explored, including somatic
cell reprogramming (using Lmx1a, Nurr1, Foxa2, En1 and Pitx3) [41,42]; however, these are out of scope of the
present work. The main objective of a cell therapy applied to PD is to obtain DA progenitors. The identity of the
progenitors is putatively marked by co-expression of the floor plate markers, FOXA2 and LMX1A, and the ability
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Figure 1. A timeline of ventral midbrain dopaminergic cell transplantation progression over five decades. Highlights include the first
transplantations in 1987 and 1992; different protocols that have been developed to produce transplantable vmDA progenitors and the
latest protocol from Lund University (Kirkeby et al.).
hESC: Human embryonic stem cells; vmDA: Ventral midbrain dopaminergic.
to produce dopamine, signified by expression of tyrosine hydroxylase (TH). Furthermore, the specific cell nuclei are
critical, since several DA neuron groups exist, three of which (A8, A9 and A10) are found in the mesencephalon [43].
The progression & evolution of vmDA differentiation protocols
Initial differentiation protocols focussed on the production of TH+ cells since this was sufficient for dopamine syn-
thesis [44,45]. Although seemingly successful, it was apparent that these cells were inadequately specific therapeutically,
since other brain cells are TH+ and produce dopamine. Typically, these protocols were from a FOXA2-/PAX6+
neural stem lineage grown from embryoid bodies (EBs) and feeder cells with activation of SHH and FGF-8
pathways to mimic embryogenesis [41,42]. However the resultant cells had reduced viability post-transplantation
and formed nonspecific axonal outgrowth in rats [33], demonstrating that dopamine production (TH+) is not the
sole requisite for therapeutic benefit, as the cells were not adequately specified into the vmDA A9 group [46–49].
Taking influence from embryogenesis, subsequent protocols were rigorous in recapitulating patterning factors
and morphogens, facilitating more efficient vmDA neuroprogenitors. Chambers et al. introduced the important
concept of the dual SMAD inhibition approach, which went on to form the basis of future neural differentiation
protocols that followed [16,33,50–52]. This approach initially induces hESC neural induction, followed by patterning
toward ventral mesencephalic fate [37]. The dual SMAD approach inhibits BMP and TGF-β, resulting in feeder-
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Figure 2. Illustrative product manufacturing timeline of a cell therapy product highlighting different assays that can be employed at
different stages. The stages include a master cell bank that undergoes pluripotent cell expansion to create a working cell bank, which is
then used to differentiate the cells into the cell product. The different assays address varying objectives such as assuring product purity,
safety, identity, viability and potency.
free, efficient neural induction in the presence of RHO kinase inhibitor. The inhibition is dual, as blocking one
pathway is insufficient for neural conversion. The addition of both noggin and SB431542 blocks BMP and TGF-β
signaling, resulting in neuroectoderm differentiation by blocking SMAD transduction and decreasing pluripotency
markers including Oct3/4 (POU5F1) [37].
Although the dual SMAD approach afforded neural induction, adjustments were necessary to ensure appropriate
vmDA patterning trajectories. Kriks et al. demonstrated that the desired specificity into vmDA was incorrect as
WNT/β-catenin signaling was not initiated. The introduction of glycogen synthase kinase 3 inhibitor (GSK3i) into
the in vitro differentiation process allowed for an iteration that activated the WNT/β-catenin pathway, affording
ventral-caudal patterning, resulting in midbrain cells with high co-localization of LMX1A and FOXA2 [53].
Since 2012, the dual SMAD and GSK3i approach has formed the basis of vmDA differentiation protocols [36,54].
Grealish et al. used this for preclinical studies and animal models, demonstrating vmDA-specified cells are capable of
innervation without overgrowth or progeny [18,55]. The functional cells have long-term survival post-transplantation,
produce dopamine and demonstrate improved motor behavior in rats [56,57]. Kirkeby et al. have since produced a
series of hESC laminin-based protocol iterations using the dual SMAD approach and GSK3i. Dual SMAD and
GSK3i protocols have produced in vitro yields ≥75% vmDA-identity cells, resulting in functional recovery of
motor behavior in PD animals [33,37].
Challenges & considerations for vmDA nNeuron manufacturing translation
Evidently mimicking embryogenesis is the most appropriate basis for contemporary hESC differentiation protocols.
The challenges remaining concern addressing translational requirements to achieve robust manufacturing processes
capable of meeting clinical need and scale. It is important that protocols can be reliably scaled-up using defined
components and reagents to ensure good manufacturing practice compliance. This requires manufacturing process
considerations to satisfy regulatory elements such as product quality and purity. This can be achieved by employing
adequate process controls and validation assays, including karyotyping, phenotype analysis and endotoxin testing
at appropriate time points throughout the manufacturing process (Figure 2) to characterize the product to ensure
both efficacy and safety [58]. This is an onerous task with CTPs as they are a living entity and the cells themselves are
the product and not just as part of the process, unlike to antibody production. The following sections highlight key
considerations for process and protocol development that can translate efficiently and effectively into a manufactured
CTP (Figure 3).
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Figure 3. Process map of the key stages of cell therapy product development. Starting with conception of the product and ending with
clinical or commercial product manufacture. The stages of conception and preclinical studies should be carried out with process
translation and manufacture in mind; early consideration of the next steps can facilitate the generation of efficient, robust and
well-informed protocols for CTP manufacture.
CTP: Cell therapy product.
Purity
Traditional pharmaceuticals assure high purity, however purity presents greater challenges for CTPs [59] due to the
inherent living nature of cells, which interact with intrinsic and extrinsic factors. Unpredictable process variables pose
problems where high purity yield governs functionality and efficacy. For instance, only vmDA would be required
to ensure efficacy and innervation of the correct cell type into the appropriate regions of the dorsal striatum.
Understandably, regulators expect proof of high purity, assuring that only the desired cells are procured for patients
as undesired cell types may have a detrimental or unknown effect [60]. The challenge remains in achieving high purity
with such complex products in other words, ensuring all cells are differentiated or manipulated to the desired state
and, crucially, retain that state from bench to patient. This is important from a safety perspective and is scrutinized
by regulators, since undesired cells may cause unwanted or unforeseen effects. This would be highly problematic
and should be addressed through rigorous functionality testing and clear understanding of the MOA. Ideally, when
a dossier is filed to the regulators purity, measures within the manufacturing process should be pre-established. In
the case of vmDA manufacturing, appropriate cell identification and sorting assays, including magnetic-activated
cell sorting and fluorescence-activated cell sorting should be considered and applied throughout the whole product
development cycle, resulting in robustly validated purity release criteria for each batch. Furthermore, testing for
the absence of bacteria, fungi and mycoplasma is essential; there are many techniques and organizations that can
be employed to carry out such screening process [59,61,62]. In some cases, if accredited, in-house tests can be used to
screen the product and this can be integrated into the quality management of the development and manufacturing
process [63,64]. It is important to note that tests and interventions to remove specific pathogens must consider
that cells are a living material and therefore cannot undergo rigorous sterilization and purification steps, such as
irradiation, that occurs during the manufacturing process of traditional pharmaceuticals.
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Identity
Undesired cells (remnant pluripotent cells) remaining in the product when administered to the patient, may alter
the MOA or result in spontaneous tumorigenesis. Cluster of differentiation markers are a prominent method of
characterizing cells via surface molecules forming part of a product’s target specification profile [62,65]. For instance,
the co-expression of FOXA2 and OTX2 alludes to differentiation toward a vmDA cell lineage. However, like many
aspects of CTPs, there are nuances presenting identification challenges, since similar cluster of differentiation marker
combinations occur on very different cell types; or expression profiles are transient [66]. The European Medicines
Agency (EMA) states “identity of cellular components should be based on phenotypic and/or genotypic markers” [67].
Consequently, test methods must be cell specific. When addressing phenotype, relevant analyses should include gene
expression, antigen presentation and specific biochemical activity in an orthogonal manner [58,61]. For allogeneic
CTPs, it is also imperative that identity profiles include histocompatibility markers, since cells will be scrutinized
by the immune system. For vmDA cell transplantation, this is essential as the cells could be rejected, resulting in
no innervation and inefficacy of the vmDA product.
Tumorigenicity
Tumorigenesis is a high risk potential for CTPs, particularly those using heavily manipulated cells or genetically
edited cells. The transformation processes they undergo could result in chromosomal instability and genetic
aberrations, consequently presenting an obstacle for regulatory authorization [67,68]. This relates back to the issue
of purity, in the event that pluripotent cells are present in the end product, there is a risk that the cell would
continue to proliferate and potentially become tumorigenic. For this reason, post-mitotic vmDAs are desired for
transplantation, however the use of post- mitotic neuronal cells presents a dilemma in terms of decreased viability
and integration of the cells. Thus, formulation of the cells and transplant cell numbers should adequately account
for this, to ensure potency and efficacy of the product are retained. When using unestablished cell lines, karyology
tests should be considered to investigate the tumorigenic potential of the cells as recommended by the EMA and
US FDA [69], particularly when the cells themselves would be transplanted into the patients. The challenge is
that CTPs may require stem cell use, extended cultures, banking and growth factors, all of which may result in
tumorigenic profiles. The EMA states: “Use of cell lines known to be tumorigenic or to possess abnormal karyology
should be evaluated in terms of risk–benefit for each product application” [69]. The FDA also employs a risk-based
case-by-case approach to tumorigenicity analysis, which encourages for the most appropriate assays to be used that
allow sufficient duration of time for any potential tumors to form.
Potency
According to the EMA, a cellular product should be able to demonstrate the intended biological effect that is
applicable to its clinical therapeutic response [70]. Similarly, the FDA describes potency as the ability of a cellular
product to provide a specific biological result that can be validated by appropriate laboratory analysis and clinical
evidence [64]. Sometimes this is easily proven, however when potency tests must also show clinically meaningful
changes it becomes difficult for some CTPs to demonstrate potency prior to human clinical trial data. For instance,
in the case of PD, fluorodopa positron emission tomography is used to measure dopamine activity in patient;
clinical changes in health utility are often measured by cognitive behavior assessments including the Unified PD
Rating Scale and the Hoehn and Yahr scale. Due to the complex nature of CTPs, until this clinical data is available,
developers may face unanswerable questions regarding product potency. However, in vitro and/or in vivo assays,
or assays based on surrogate markers [61,62,64] including gene expression profiles and flow cytometry immunoassays
can be employed to determine product potency. For example, dopamine release assays for vmDA neuroprogenitors
can be used to ascertain potential dopamine levels; this information can be linked to the minimum dopamine levels
required to provide improvements in motor symptoms. Such an assay would benefit from being nondestructive to
the cells while having the ability to be employed in real time, as dopamine release would be a critical time point
in the differentiation of vmDA. However, development of a potency assay for a CTP that is not at its functional
end point presents many challenges. For instance with vmDA neuroprogenitors their axonal outgrowth cannot be
measured using an assay prior to transplantation, without having to mature the cells. In addition, their potential
to release dopamine cannot be measured at the progenitor stage; however, the use of markers such as TH could be
used as a predictive indicator that the cells will produce dopamine within the dorsal striatum once engrafted.
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Supply chain
Supply chain reliability is often overlooked; however, reagents require batch validation with deviances being
accounted for, or the demonstration of nondetrimental effects on the end product [61]. Therefore, it is important
to consider reagents during process development to ensure manufacturing scalability. Furthermore, when assays
come in contact with the product, it is essential that good manufacturing practice-compliant reagents are used as
the end product will be in introduced into patients, and therefore it should be free of any harmful substances.
Supply chain control and contingences are recommended to reduce variability, especially if tested within the design
space [62]. This is pertinent for the differentiation of vmDA neuroprogenitors as the differentiation process requires
a range of different supplemental and small molecule reagents. Suitably, these reagents should be simultaneously
available or appropriate validated substitutes should be identified, to ensure that the differentiation process and
product manufacturing is robust and amenable to supply chain changes. The latter activity may help overcome
comparability issues further down the product timeline, especially if suppliers become obsolete. For supply chain
management, product and assay development should be reliable and effective while considering associated costs, as
hindrances to many CTPs are their cost-intensive development. This links to the need to consider reagent use and
understanding the overall process unit costs [38].
Quality by design; the importance of defining product characteristics
The aforementioned challenges are addressed or well mitigated in well-established industries including antibody
and pharmaceutical production, thus providing a learning platform for CTPs. An established manufacturing tool
in pharmaceutical production is Juran’s concept of Quality by Design (QbD). QbD facilitates product and process
development that is data, risk and knowledge driven, with the intention of ensuring that quality is built into the
product from the outset [71–73]. QbD key aspects include: defining quality target product profiles (QTPP) which
are utilized to highlight the desired specifications, or critical quality attributes (CQAs), which ensure the desired
product quality [72,74,75]. Having defined QTPP and CQAs precedes identification of critical material attributes
and critical process parameters (CPPs) [74,76]. QbD concepts facilitate protocol and process development conceived
with control strategies in place, ensuring that the QTPP is met in every production run; via identification and
understanding the design space in which the CPPs result in the CQA and QTPP [74–76]. The design space helps
developers attain process controls given the CPPs, and furthermore the use of process analytical technology (PAT)
allows for iterative, data rich, informative development processes able to identify process capability [72,77].
GSK3i and SHH concentrations are integral CPPs for ventral mesencephalic patterning [33,78]. The lack of GSK3i
and SHH results in dorsal fated neurons, while high concentrations result in hindbrain neurons; neither of these
neuronal subtypes are TH+ [33]. Therefore, it is important to determine the appropriate concentrations of GSK3i
and SHH to achieve the desired vmDA neuronal subtype [36,40,49,79]. Carrying out experimental investigations of
the appropriate concentrations of these small molecules is essential to provide an understanding of the design space
in which the desired CQAs can be obtained [74,76].
Characterization
Characterization is fundamental to CTP manufacturing; it is important to characterize and identify both input
critical material attributes and output cells of a manufacturing process [62,80,81]. This facilitates input quality, en-
suring materials are process appropriate; output characterization evaluates product manufacturing success [72,74,75].
CQAs are integral to product understanding and need defining prior to approval. CQAs are functionality-based
characteristics, which can be physical or chemical attributes linked to potency, identity and/or purity [59,61,62].
These characteristics can be identified by cell morphology, phenotypic markers and secreted factors, which can be
potentially linked to functionality and clinical response in other words, detection of secreted dopamine [62]. It is
important that developers are selective and robust in their characterization, for instance distinct marker profiles
should be used to confirm identity. This is crucial for CTPs such as vmDA progenitors for transplantation as subtle
differences appear between DA neurons and neighboring neuronal cells. However, vmDA lineages restricted to
the caudal ventral midbrain can be identified by FOXA2, LMX1A, CORIN, OTX2 and EN1 co-expression [18,33].
Therefore, using high specificity characterization criteria is a necessity for robust CTP assay development. Char-
acterization during product development can provide validated and quantitative data applicable to potency assay
development. Flow cytometry, genetic analysis and metabolite data are robust methods for analyzing identity, which
can be used to track changes during expansion or differentiation. Correspondingly, potency assays based on MOA
and cell characterization could be used to characterize products prerelease [18].
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Phenotypic markers
Phenotypic markers can be used to ensure the CPPs and design space efficiently yield the desired CQAs. For
instance, the small molecule concentrations and cell densities result in the desired cell markers and thus the CQAs
in other words, a DA phenotype. Intracellular and extracellular markers can be transient, and thus are appropriate
for monitoring process progression, including differentiation, using techniques such as flow cytometry or gene
expression analysis. For a vmDA product, the input and output cell types have distinctive identity profiles. Positive
expression of SSEA-4 and Oct3/4 signifies undifferentiated cells, while decreased expression of these markers and
transient presence of PAX6 demonstrates neural stem cell lineage progression [37]. The desired differentiated end
product can be identified by FOXA2 and OTX2 co-expression [33]. Therefore, these markers can be assigned as
CQAs since expression corresponds to specific stages, permitting development of in-process assays set against these
CQAs. Furthermore, markers such as EN1 and TH have been linked to vmDA function in animal models.
Technology
Innovative adaption and transformation of technologies to meet new processes and product requirements is becom-
ing commonplace. Instances include the creation of integrated systems resembling a modular process comprised of
complementary technologies [65]. These aim to provide essential CTP monitoring capabilities, production control
and production capacity to meet potential clinical demand. Scale up technologies are necessary for efficient manufac-
turing, however adequate control and monitoring technologies are equally essential for downstream manufacturing
process optimization such as cell sorting, purification and filling [65]. Technologies such as fluorescence-activated cell
sorting, automated cell counting and automated controlled rate freezing offer some solutions to ensure homogenous
cell populations, ascertain cell viability and consistency of product manipulation on site, respectively [82–85].
Truly integrated inline systems, capable of monitoring, characterizing and sorting cells would allow for attainment
of highly pure products, facilitating both process control and quality assurance. Furthermore, nondestructive PAT
analyzing cell-secreted substances in real-time would allow for process mapping, as discrete secretome profiles
are evident throughout differentiation. Failure to detect defined metabolites or secretome can act as a go/no-go
decision tool for the differentiation and manufacturing processes, allowing for process interventions to evaluate
whether the failure to detect metabolites or the secretome would impact the final product’s quality and functionality.
Furthermore, substance detection that is concomitant to product functionality in other words, secreted dopamine,
could be a powerful potency assay. This can be achieved with PATs directly linked to the culture vessel that detect
the desired substance in other words, metabolite analyzers, allowing for real-time process analysis and presenting a
powerful tool for process development monitoring and CPP capability.
Conclusion
The growth of the cell therapy industries and the knowledge of vmDA differentiation suggests that CTPs for PD
therapy is imminent. However, the translational space to bridge basic research into manufactured products is often
neglected, which has retarded CTPs. A QbD mindset that fully characterizes a product throughout its life cycle and
aids in the development of CQA informed in-process assays provides a powerful tool set for developers. This tool
set provides product and process understanding which developers can use to address manufacturing challenges such
as cell identification and assay development. A proactive stance to assay development is encouraged, considering
how the product works and batch analysis at an early stage can mitigate risks during later stages of process and
manufacturing development. A plethora of information demonstrating a clear understanding of the process and
product is likely to favored by regulators, demonstrating due diligence throughout the development stages. An
in-depth understanding of both process and product design spaces makes the product amenable to change, where
necessary, negating further comparability studies and extensive paperwork. This permits informed, less hindered
pathways to product regulatory authorization as ‘early and sustained investment in a bonafide potency program is
essential for maximizing a product’s commercial success’ [62].
Future perspective
Current CTP limitations include the need for in-depth product understanding to ensure product potency, safety
and purity. New technologies require development and validation to address issues of production scale-up to
meet clinical need; assays are required for process control, validation and release. Prior to clinical realization, an
understanding of production processes is required to implement process changes which is essential for process
control. Identification of key parameters forms the basis of process tolerances, allowing for validated, adaptive
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manufacturing processes. This enables greater process control and yield while withstanding regulatory scrutiny.
The application of these key translational considerations and recommendations will enable successful, robust and
reproducible CTP-manufacturing.
Executive summary
Therapies for the treatment of Parkinson’s disease
• The development of robust protocols for the production of ventral midbrain dopaminergic neuron (vmDA)
progenitor cells for the treatment of Parkinson’s disease has been used as an exemplar case in this review.
• Transplantation of vmDA neuroprogenitors has been shown to successfully reverse symptoms of Parkinson’s
disease. However, current research protocols are presently not optimized into reproducible, robust
manufacturing processes.
In vitro differentiation of human embryonic stem cells into vmDA neurons
• Successful protocol derivation is dependent upon a prior knowledge and understanding of developmental in vivo
cellular cues and processes.
Challenges & considerations for vmDA neuron manufacturing translation
• Despite significant research and economic growth in the field of regenerative medicine and cell therapy
industries the full potential has not yet been; realized this has in part been retarded by both process and
manufacturing stances.
• In order to be fully translational and clinically relevant, cell therapy products (CTPs) must be reliably
manufactured and scaled up using defined good manufacturing practice-compliant processes, components and
reagents.
Quality by design, the importance of defining product characteristics
• Manufacturing processes must satisfy strict regulatory requirements including purity, validity and safety.
Employing quality by design from the outset ensures that process development is data, risk and knowledge
driven, thus ensuring quality CTPs.
• Protocol and process development must be conceived with control strategies in place to ensure that quality
target profiles are met every time. Characterization and defined critical quality attributes are fundamental to
this, in terms of both cellular input and output.
Conclusion
• An in-depth understanding of process and product design enables cellular products to be amenable to change,
which negates the need for further comparability studies and extensive paperwork.
• A proactive stance to assay development is vital, this includes a consideration of how the product works and the
inclusion of early-stage batch analysis to mitigate risks during later stages of process and manufacturing
development.
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